NEW YORK (TheStreet) -- Horizon Pharma (HZNP) - Get Report shares are up 9.95% to $20.97 in early market trading on Friday after the biopharmaceutical company reported its fourth quarter earnings results before the opening bell today.

The Dublin, Ireland-based company reported a fourth quarter net loss of $31.6 million, or a profit of 27 cents per share on an adjusted basis on revenue of $103.8 million, a 245% increase of the same period last year. Analysts on average were expecting the company to report a fourth quarter EPS of 21 cents per share on revenue of $95.54 million.

Exclusive Report:Jim Cramer's Best Stocks for 2015

Additionally, the company raised its fiscal 2015 earnings guidance to be in line with analysts' expectations. The company now expects to generate revenue in the $450 million to $475 million range, up from the $425 million to $450 million it had previously forecast, and in line with Capital IQ's $461 million estimate.

The company also raised its EBITDA estimates to between $170 million and $190 million from its previous view of between $160 million and $180 million.

Horizon moved its operations to Ireland following last year's tax inversion purchase of Vidara Therapeutics. The company was the first major American pharmaceutical company to successfully complete a tax inversion deal, according to Real Money Pro's Bret Jensen.

TheStreet Ratings team rates HORIZON PHARMA PLC as a Sell with a ratings score of D-. TheStreet Ratings Team has this to say about their recommendation:

"We rate HORIZON PHARMA PLC (HZNP) a SELL. This is driven by a few notable weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The area that we feel has been the company's primary weakness has been its generally higher debt management risk."

Highlights from the analysis by TheStreet Ratings Team goes as follows:

Image placeholder title

HZNP

data by

YCharts